Cannabix Technologies Delivers First Breath-Based DOT-Like Multi-Drug Testing Panel for Recent-Use Detection

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Cannabix Technologies Delivers First Breath-Based DOT-Like Multi-Drug Testing Panel for Recent-Use DetectionAuthor of the article:VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing technologies is pleased to announce that it has made first commercial delivery of its new breath-based multi-drug test panel. The panel is modeled after the drug classes included in the U.S. Department of Transportation’s (DOT) federally mandated urine drug testing program, including amphetamines/methamphetamines, cocaine, marijuana (THC), opiates, and phencyclidine (PCP) (the “DOT-like Panel”).THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThis advertisement has not loaded yet, but your article continues below.This first deployment follows the validation by Omega Laboratories, Inc. of a laboratory developed test method utilizing the Cannabix Breath Collection Unit (“BCU”) and Breath Cartridge technologies. The validated method supports the simultaneous detection of multiple drug classes from breath samples, expanding Cannabix’s breath testing capabilities beyond cannabinoids and demonstrating the versatility of its technology.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againFigure 1. Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies.Unlike urine and hair testing, which can identify historical drug exposure over days, weeks, or months, employers and other decision-makers are often seeking information about more recent drug use. Breath testing is intended to target a substantially shorter detection window following drug consumption. Cannabix’s breath-testing technology is designed to help address this gap by focusing on a shorter detection period, ranging from 15 minutes to 4 hours after use, which provides a more relevant time window in safety-sensitive situations. By combining observed breath collection, chain-of-custody procedures, split-sample capability, and laboratory mass spectrometry confirmation, the Company’s breath-based DOT-like testing model is designed to support drug testing programs where scientific rigor, evidentiary defensibility, and operational practicality are important requirements.This advertisement has not loaded yet, but your article continues below.The Company’s new breath-based multi-drug test panel option expands Cannabix’s breath-testing platform beyond marijuana detection and is targeted toward workplace testing, criminal justice and treatment monitoring programs, post-incident investigations, reasonable-suspicion testing, and other safety-sensitive environments where recent-use assessment is a key objective.About Cannabix Technologies Inc.Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in workplaces, law enforcement, and a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.comThis advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.On behalf of the Board of DirectorsCEOCannabix Technologies Inc.For further information, contact the Company at info@cannabixtechnologies.comCautionary Statement Regarding Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements may include, but are not limited to, statements regarding the development, validation, performance, commercialization, deployment, market acceptance, regulatory considerations, and potential applications of the Company’s breath-testing technologies, including its marijuana breath-testing programs, multi-drug breath-testing initiatives, Breath Collection Unit (“BCU”), Breath Cartridge technologies, and related products and services. Forward-looking statements are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “may,” “will,” “could,” “should,” and similar expressions. Forward-looking statements are based on management’s current expectations, assumptions, and beliefs as of the date of this news release. Actual results may differ materially from those expressed or implied by such forward-looking statements due to various risks and uncertainties, including but not limited to research and development outcomes, technology performance, validation results, regulatory developments, intellectual property protections, commercial adoption, industry acceptance, competitive factors, availability of financing, and general economic and market conditions. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.